[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20001548L - Endotelinantagonist og en renin-angiotensinsystem inhibitor som et kombinert preparat - Google Patents

Endotelinantagonist og en renin-angiotensinsystem inhibitor som et kombinert preparat

Info

Publication number
NO20001548L
NO20001548L NO20001548A NO20001548A NO20001548L NO 20001548 L NO20001548 L NO 20001548L NO 20001548 A NO20001548 A NO 20001548A NO 20001548 A NO20001548 A NO 20001548A NO 20001548 L NO20001548 L NO 20001548L
Authority
NO
Norway
Prior art keywords
renin
combined preparation
angiotensin system
endothelin antagonist
system inhibitor
Prior art date
Application number
NO20001548A
Other languages
English (en)
Other versions
NO20001548D0 (no
NO324382B1 (no
Inventor
Klaus Muenter
Michael Kirchengast
Horst Korioth
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19742717A external-priority patent/DE19742717A1/de
Priority claimed from DE1997143141 external-priority patent/DE19743141A1/de
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of NO20001548L publication Critical patent/NO20001548L/no
Publication of NO20001548D0 publication Critical patent/NO20001548D0/no
Publication of NO324382B1 publication Critical patent/NO324382B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/556Angiotensin converting enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20001548A 1997-09-26 2000-03-24 Kombinasjon av endotelinantagonist og en reninangiotensinsystem(RAS)-inhibitor, farmasoytisk preparat som omfatter kombinasjonen, samt fremstilling av preparatet og anvendelse av kombinasjonen. NO324382B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19742717A DE19742717A1 (de) 1997-09-26 1997-09-26 Pharmazeutische Kombinationspräparate
DE1997143141 DE19743141A1 (de) 1997-09-30 1997-09-30 Pharmazeutische Kombinationspräparate
PCT/EP1998/005773 WO1999016445A1 (de) 1997-09-26 1998-09-10 Endothelin antagonist und renin-angitensin systems hemmer als kombinationspräparate

Publications (3)

Publication Number Publication Date
NO20001548L true NO20001548L (no) 2000-03-24
NO20001548D0 NO20001548D0 (no) 2000-03-24
NO324382B1 NO324382B1 (no) 2007-10-01

Family

ID=26040370

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001548A NO324382B1 (no) 1997-09-26 2000-03-24 Kombinasjon av endotelinantagonist og en reninangiotensinsystem(RAS)-inhibitor, farmasoytisk preparat som omfatter kombinasjonen, samt fremstilling av preparatet og anvendelse av kombinasjonen.

Country Status (15)

Country Link
US (1) US6329384B1 (no)
EP (1) EP1014989B1 (no)
JP (2) JP4917707B2 (no)
KR (1) KR100623121B1 (no)
CN (1) CN1187050C (no)
AT (1) ATE257706T1 (no)
AU (1) AU750755B2 (no)
BR (1) BR9812531A (no)
CA (1) CA2304712C (no)
CZ (1) CZ299741B6 (no)
DE (1) DE59810600D1 (no)
ES (1) ES2214734T3 (no)
HU (1) HU226454B1 (no)
NO (1) NO324382B1 (no)
WO (1) WO1999016445A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
CZ299741B6 (cs) * 1997-09-26 2008-11-05 Abbott Gmbh & Co. Kg Kombinace endotelinového antagonisty a RAS inhibitoru a její použití, farmaceutický prostredek s jejím obsahem a zpusob výroby tohoto prostredku
US20070196510A1 (en) * 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
JP2009256209A (ja) * 2006-02-17 2009-11-05 Gilead Colorado Inc 降圧療法
AU2007217100A1 (en) * 2006-02-17 2007-08-30 Gilead Colorado, Inc. Antihypertensive therapy
EP2086518A2 (en) * 2006-11-09 2009-08-12 Gilead Colorado, Inc. Darusentan oral dosage form
EP2091539A1 (en) * 2006-12-12 2009-08-26 Gilead Colorado, Inc. Ambrisentan combined with a renin inhibitor for hypertensive disorder
EP2545920A1 (en) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
US20090076119A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched ramipril
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022978A1 (en) * 1995-01-27 1996-08-01 Rhone Poulenc Rorer Limited Substituted phenyl compounds as endothelin antagonists
ES2141197T3 (es) * 1993-03-19 2000-03-16 Merck & Co Inc Derivados del acido fenoxifenilacetico.
ES2154277T3 (es) * 1993-07-15 2001-04-01 Hoffmann La Roche Combinacion farmaceutica que contiene un inhibidor del sistema renina-angiotensina y un antagonista de endotelina.
DE19533023B4 (de) * 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
MX9703988A (es) * 1994-12-12 1998-02-28 Omeros Med Sys Inc SOLUCIaN Y MÉTODO DE IRRIGACIaN PARA LA INHIBICIaN DEL DOLOR, LA INFLAMACIaN Y ES ESPASMO.
DE19636046A1 (de) * 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
DE19652374A1 (de) 1996-12-04 1998-06-10 Schering Ag Verwendung von Endothelin-Konjugaten in der Therapie, neue Endothelin-Konjugate, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
ID26234A (id) 1996-12-18 2000-12-07 Basf Ag Turunan-turunan asam karboksilat heterosiklik, pembuatan dan penggunaannya sebagai antagonis-antagonis reseptor endotelen
CZ299741B6 (cs) * 1997-09-26 2008-11-05 Abbott Gmbh & Co. Kg Kombinace endotelinového antagonisty a RAS inhibitoru a její použití, farmaceutický prostredek s jejím obsahem a zpusob výroby tohoto prostredku

Also Published As

Publication number Publication date
KR100623121B1 (ko) 2006-09-12
CA2304712C (en) 2008-04-29
EP1014989A1 (de) 2000-07-05
CZ20001107A3 (cs) 2000-08-16
US6329384B1 (en) 2001-12-11
HU226454B1 (en) 2008-12-29
CN1187050C (zh) 2005-02-02
WO1999016445A1 (de) 1999-04-08
AU9539598A (en) 1999-04-23
CZ299741B6 (cs) 2008-11-05
JP4917707B2 (ja) 2012-04-18
DE59810600D1 (de) 2004-02-19
ATE257706T1 (de) 2004-01-15
AU750755B2 (en) 2002-07-25
BR9812531A (pt) 2000-07-25
CA2304712A1 (en) 1999-04-08
CN1271283A (zh) 2000-10-25
ES2214734T3 (es) 2004-09-16
NO20001548D0 (no) 2000-03-24
JP2012046531A (ja) 2012-03-08
KR20010030713A (ko) 2001-04-16
NO324382B1 (no) 2007-10-01
JP2001517704A (ja) 2001-10-09
EP1014989B1 (de) 2004-01-14
HUP0004298A3 (en) 2002-06-28
HUP0004298A2 (hu) 2001-11-28

Similar Documents

Publication Publication Date Title
NO975244L (no) 5-ring-heterocykluser som inhibitorer av leukosyttadhesjon og VLA-4-antagonister
TR199800759T2 (xx) Protein Kinaz C �nhibit�r�.
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
NO20001979L (no) Anvendelse av inhibitorer av renin-angiotensin-systemet
NO942650L (no) Farmasöytisk kombinasjonspreparat
NO20001548L (no) Endotelinantagonist og en renin-angiotensinsystem inhibitor som et kombinert preparat
SE9601556D0 (sv) New pharmaceutical formulation of a thrombin inhibitor for parenteral use
ATE203519T1 (de) Chinolinderivate als antimalariamittel
DK1119359T3 (da) 2-methyl-thieno-benzodiazepinformulering
ATE266420T1 (de) Kombinationspräparat, das selektive nmda nr2b- antagonisten und cox-2 inhibitoren enthält
BR9809848A (pt) Composição
AU1023497A (en) Tissue factor - kunitz domain fusion proteins as factor viia inhibitors
NO20014855D0 (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
BR0110902A (pt) Inibidores de mmp-9/mmp-2
ATE239479T1 (de) Endothelin antagonist und betarezeptorenblocker als kombinationspräparate
DK0910379T3 (da) Plaster til transdermal påføring af pergolid
UY26893A1 (es) Combinación farmacéutica de antagonistas de la angiotensina ii e inhibidores de la enzima de conversión de la angiotensina i
WO2002016432A3 (en) Two receptors of meiosis activating sterols designated sam1a and sam1b
WO2002016433A3 (en) Two receptors of meiosis activating sterols designated sam1a and sam1b
HUP9900606A2 (hu) 5-HT3 Receptor antagonisták mozgászavar kezelésére
ECSP972253A (es) Composicion farmaceutica: nueva formulacion y su uso en el tratamiento y/o profilaxis de ciertos trastornos
SE9100950L (sv) Vvs-armatur foer tvaettstaell

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ABBVIE DEUTSCHLAND GMBH & CO AG, DE

MM1K Lapsed by not paying the annual fees